Clinical Trials
337 trialsStudy BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
FORAGER-2
Eli Lilly and Company
TroFuse-031
Merck Sharp & Dohme LLC
FORAGER-1
Eli Lilly and Company
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
ADVANCED-2
Protara Therapeutics
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
BAYOU
AstraZeneca
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
ENVISION
UroGen Pharma Ltd.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
EV-309
Astellas Pharma Inc
SunRISe-1
Janssen Research & Development, LLC
SunRISe-2
Janssen Research & Development, LLC
TAR-210
Janssen Pharmaceutical K.K.
SunRISe-3
Janssen Research & Development, LLC
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
panSOHO
Bayer
HIVEC
AC.TA. S.r.l.
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
MK-3475-992
Merck Sharp & Dohme LLC
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
enGene, Inc.
BCG for Therapeutic Use Phase â…¢ Clinical Trial
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
EMD Serono
MK-3475-04D
Merck Sharp & Dohme LLC
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
MK-3120-003
Merck Sharp & Dohme LLC
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Pfizer
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
VOLGA
AstraZeneca
VIABLE
Virtuoso Surgical, Inc.
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
PRESERVE-009
OncoC4, Inc.
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
CG Oncology, Inc.
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
INTerpath-011
Merck Sharp & Dohme LLC
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
exBOND
CG Oncology, Inc.
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc.
ARC-25
Arcus Biosciences, Inc.